australia's next csl?, page-12

G'day ASH81,

Another one of the "key findings of the Australian 30 patient venous ulcer trial of VitroGro" that I found quite illuminating was the "Reduced average venous ulcer area from 6.6 to 3.8 cm sq (43%) occurred in 24 days". (Page 3 of Tissue Therapies Prospectus).

This 43% reduction in the ulcer area is significant because these were patients (as you said in your post) who "had not responded to expert care" for an average time of eleven (11) months before VitroGro treatment.

I know (as bumkins indicates) that it is only conjecture at this stage that patients suffering venous ulcers for a much lesser time would respond better to treatment with VitroGro than conventional treatment, but the odds are certainly on Tissue Therapies side that this would be the case.

The "proof will be in the pudding" when the clinical trial results are handed down by Professor Harding hopefully commencing in July 2011. I look forward to these results, not the least because VitroGro will relieve a great deal of suffering for those who have endured prolonged periods with venous ulcers as well as the constant worry of possible amputation of a limb.

Regards,

Goggo